Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

1.2K
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.2K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

627
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
627
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

970
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
970
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

618
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
618
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

337
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
337
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

317
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
317

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

B Cells and B Cell Depletion in Autoimmunity and Atherosclerosis.

Life (Basel, Switzerland)·2026
Same author

Autoantibodies Drive Fcγ Receptor-Dependent Colon Inflammation During Immune Checkpoint Blockade.

bioRxiv : the preprint server for biology·2026
Same author

Editorial: Genetic underpinnings of Alzheimer's and Parkinson's: insights and innovations.

Frontiers in genetics·2026
Same author

The Impact of Dementia Caregiving on the Health of the Spousal Caregiver.

Medicina (Kaunas, Lithuania)·2026
Same author

Monoclonal antibodies and small molecules: on the cutting edge of Alzheimer's disease therapy.

Frontiers in cell and developmental biology·2026
Same author

Differential Cytokine Profiles in Prostate Cancer Under Treatment: Implications for Prognosis and Synergistic Therapy Design.

Cancers·2026

Related Experiment Video

Updated: Apr 4, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K

Cholesterol Metabolism in CKD.

Allison B Reiss1, Iryna Voloshyna1, Joshua De Leon1

  • 1Department of Medicine and Winthrop Research Institute, Winthrop University Hospital, Mineola, NY.

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|September 5, 2015
PubMed
Summary
This summary is machine-generated.

Patients with chronic kidney disease (CKD) face high coronary artery disease risk due to inflammation disrupting lipid balance. Dysfunctional high-density lipoprotein and elevated triglycerides contribute to this, impacting vascular health.

Keywords:
Cholesterol transportatherosclerosiscardiovascular disease (CVD)chronic kidney disease (CKD)dyslipidemiahigh-density lipoprotein (HDL)inflammationlipid-lowering therapylow-density lipoprotein (LDL)nontraditional risk factorreactive oxygen species (ROS)statin therapyuremic toxins

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.9K
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

825

Related Experiment Videos

Last Updated: Apr 4, 2026

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

1.9K
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
10:31

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice

Published on: May 2, 2025

825

Area of Science:

  • Nephrology
  • Cardiology
  • Biochemistry

Background:

  • Chronic kidney disease (CKD) significantly increases coronary artery disease (CAD) risk.
  • Traditional cardiovascular disease (CVD) risk factors inadequately explain high CVD prevalence in CKD patients.
  • Both CKD and CVD are inflammatory conditions impacting lipid metabolism.

Purpose of the Study:

  • To review disrupted cholesterol transport in CKD.
  • To present evidence on the uremic environment's effect on vascular lipid accumulation.
  • To explore preventative and treatment strategies for dyslipidemia in CKD.

Main Methods:

  • Review of clinical and preclinical evidence.
  • Analysis of lipid metabolism and cholesterol transport in CKD.
  • Examination of the impact of inflammation on lipoprotein function.

Main Results:

  • CKD-associated dyslipidemia involves elevated triglycerides and decreased, dysfunctional high-density lipoprotein (HDL).
  • Dysfunctional HDL loses atheroprotective properties, becoming proinflammatory.
  • Impaired triglyceride clearance and altered low-density lipoprotein (LDL) associations complicate risk assessment.

Conclusions:

  • Inflammation in CKD disrupts normal lipid balance and cholesterol transport.
  • Understanding these mechanisms is crucial for managing cardiovascular risk in CKD.
  • Novel therapeutic strategies targeting lipid metabolism are needed for CKD patients.